Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.35 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.34 |
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | NPY4R | P50391 | 4/20 | 0.33 |
| ▸ | NPY1R | P25929 | 3/20 | 0.33 |
| ▸ | NPY2R | P49146 | 2/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | GSR | P00390 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.30 |
| ▸ | TUBB | P07437 | 1/20 | 0.30 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.30 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.30 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.30 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL18920531 | 1.00 | OTC (0.35) | OTCDDAH1ARG1NPY4RNPY1R | |
| Arginine SCHEMBL8319070 | 1.00 | OTC (0.35) | OTCDDAH1ARG1NPY4RNPY1R | |
| Arginine SCHEMBL21612207 | 1.00 | OTC (0.35) | OTCDDAH1ARG1NPY4RNPY1R | |
| Arginine SCHEMBL17113849 | 0.96 | OTC (0.38) | OTCDDAH1ARG1NPY4RNPY1R | |
| Arginine SCHEMBL21273831 | 0.96 | OTC (0.38) | OTCDDAH1ARG1NPY4RNPY1R | |
| Arginine SCHEMBL23242196 | 0.96 | OTC (0.38) | OTCDDAH1ARG1NPY4RNPY1R | |
| Arginine SCHEMBL17113847 | 0.96 | OTC (0.38) | OTCDDAH1ARG1NPY4RNPY1R | |
| Arginine SCHEMBL176372 | 0.96 | OTC (0.38) | OTCDDAH1ARG1NPY4RNPY1R | |
| Arginine SCHEMBL176371 | 0.96 | OTC (0.38) | OTCDDAH1ARG1NPY4RNPY1R | |
| Arginine SCHEMBL15194711 | 0.96 | OTC (0.38) | OTCDDAH1ARG1NPY4RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146492-A1 | Novel pro-insulin having specific amino acid and/or nucleic acid modifications suitable for improved methods of insulin production are provided. Novel and highly efficient processes for preparing the proinsulin preparations and preparations containing them | STELIS BIOPHARMA PRIVATE LIMITED (IN) | 2008-06-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146492-A1 | Novel pro-insulin having specific amino acid and/or nucleic acid modifications suitable for improved methods of insulin production are provided. Novel and highly efficient processes for preparing the proinsulin preparations and preparations containing them | INSR, INSRR, IGF2BP1 | OTC 2285/4885DDAH1 246/4885ARG1 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.